tiotropium (Spiriva® Respimat®) -

tiotropium (Spiriva® Respimat®)
Information type: Drug best practice guidance
Source: All Wales Medicines Strategy Group
Specialities: Respiratory disorders
Summary
Not recommended within NHS Wales as add-on maintenance bronchodilator in adults with asthma on inhaled corticosteroids (≥ 800 micrograms budesonide daily/equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.
UKMi comment
The company submission did not present sufficient evidence to demonstrate that tiotropium (Spiriva® Respimat®) is cost-effective.
Related links: